



## Sumit Shah

- Clinical Associate Professor, Medicine - Oncology
- Clinical Associate Professor (By courtesy), Urology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Clinic E

Stanford, CA 94305

Tel (650) 498-6000      Fax (650) 736-7379

### Bio

---

#### BIO

Dr. Sumit Shah is a medical oncologist specializing in the management of advanced urologic malignancies, including prostate, bladder, kidney, and testicular cancers. He is actively involved in clinical trials, with a particular focus on novel immunotherapy agents and biomarkers to select patients most likely to benefit from therapy. His academic interests also encompass digital health technologies and innovative healthcare delivery models. He has lectured internationally on the management of urologic cancers and currently serves on the National Cancer Center Network (NCCN) Panel for testicular cancer.

Dr. Shah graduated with distinction in biomedical engineering from Duke University, earned his MD from Stanford University, and completed a Master of Public Health at Harvard University. He trained in internal medicine at the University of California, San Francisco (UCSF), where he remained on faculty for one year before returning to Stanford for his fellowship in medical oncology. He now holds a faculty position in the Department of Medicine (Oncology) at Stanford.

In addition to his clinical and research roles, Dr. Shah serves as Medical Director of Digital Healthcare Integration and Director of Infusion Services at Stanford Hospital. He is also Assistant Dean of Academic Advising in the Stanford School of Medicine.

#### CLINICAL FOCUS

- Oncology
- Prostate Cancer
- Kidney Cancer
- Bladder Cancer
- Testicular Cancer/Germ Cell Tumor
- Immunotherapy

#### ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology

- Clinical Associate Professor (By courtesy), Urology
- Member, Stanford Cancer Institute

## HONORS AND AWARDS

- Physician of the Year, honorable mention awardee, Stanford Healthcare (2026)
- US Fulbright Scholar, South Korea (2005)

## PROFESSIONAL EDUCATION

- Board Certification: Oncology, American Board of Internal Medicine (2024)
- Residency: UCSF Dept of Internal Medicine (2013) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2017) CA
- Medical Education: Stanford University School of Medicine (2010) CA
- Fellowship, Stanford University Hospital , Oncology/Hematology (2017)
- Residency, University of California, San Francisco (UCSF) , Internal Medicine (2013)
- MPH, Harvard School of Public Health (2010)
- MD, Stanford School of Medicine (2010)
- BSE, Duke University (2004)

## LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

## Research & Scholarship

---

### CLINICAL TRIALS

- Phase Ib/II Multiple ImmunotherapyBased Treatments &Combinations in UrothelialCarcinoma(MORPHEUS-UC), Not Recruiting

## Teaching

---

### STANFORD ADVISEES

#### Academic Advising Dean

David Altman, Elizabeth Asonye, Ellie Beam, Preksha Bhagchandani, Anushka Bhaskar, Alex Burgess, Timothy Chai, Michelle Chang, Sean Cheah, Kevin Chen, Maggie Chen, Mira Cheng, Suyoung Choi, Megan Chung, Shayna Cooperman, Anthony Cort, Greta Cywinska, Sofia Essayan-Perez, Allan Feng, Cesar Garcia, Lauren Ginn, Sofia Gurgel, Zoe Hughes, Edoghogho Ighodaro, Katelin Isakoff, Kendra Jackson, Candice Kim, Lauren Kim, Harrison Konsker, Chelsea Li, Sabrina Li, Michelle Lin, Daniel Liu, Longsha Liu, Shirley Liu, Isaac Longobardi, Mary Lopez Isidro, Sofia Luna, Lucy Ma, Kajal Maran, Payton Marshall, Michael Mayer, Cory McEvoy, Vilina Mehta, John Michaud, Daniel Mokhtari, Priyanka Multani, Kabungo Mulumba, George Nageeb, Michael Nedelman, Sriya Nemani, Madison Palmer, Cindy Phan, Ragini Phansalkar, James Poe, Sri Polkampally, Max Ruiz, Santiago Sanchez, Isha Sanghvi, Emily Schultz, Mihir Shah, Jason Shen, Jerry Shen, Benjamin Smith, Jodi So, Morgan Sokol, Elijah Sommer, Akshay Swaminathan, Lauren Taylor, Jason Thomas, Austin Valido, Kunal Varshneya, Andre Vu, Harsh Wadhwa, Zachary Wakefield, Songnan Wang, Christine Xu, Josiah Yarbrough, Christine Yiwen Yeh, Dave Young, Willemijn van Deursen

## Publications

---

### PUBLICATIONS

- **Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.** *European urology oncology*

Sfakianos, J. P., Basu, A., Laliotis, G., Kumarasamy, S., Rich, J. M., Kommalapati, A., Glover, M., Mahmood, T., Tillu, N., Hoimes, C. J., Selig, G., Kollipara, R., Stewart, et al  
2024

- **The Will to Go On.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Shah, S.  
2022: JCO2201188
- **Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.** *Lancet (London, England)*  
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y. n., Rubinstein, S. M., Rivera, D. R., Shete, S. n., Hsu, C. Y., Desai, A. n., de Lima Lopes, G. n., Grivas, P. n., Painter, C. A., Peters, et al  
2020
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al  
2019: JCO1802018
- **Consolidative Radiotherapy in Metastatic Urothelial Cancer.** *Clinical genitourinary cancer*  
Shah, S., Zhang, C. A., Hancock, S., Fan, A., Skinner, E., Srinivas, S.  
2017
- **Enfortumab vedotin and pembrolizumab (EVP) outcomes in patients (pts) with advanced urothelial carcinoma (aUC) and FGFR3 alterations: UNITE study analysis.**  
Cai, E., Zhang, L., Reyes, K., Thomas, Z., Jiang, C., Oh, E., Jindal, T., Zhong, J., Jaime-Casas, S., Fahey, C., Gupta, S., Shah, S., Basu, et al  
LIPPINCOTT WILLIAMS & WILKINS.2026: 668
- **Impact of prior immune checkpoint inhibitor (ICI) and interval from ICI exposure on outcomes with enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC)**  
Jindal, T., Jiang, C. Y., Cai, E. Y., Zhong, J., Oh, E., Casas, S., Bakaloudi, D., Emamekhoo, H., Zakharia, Y., Nizam, A., Milowsky, M. I., Shah, S., Basu, et al  
LIPPINCOTT WILLIAMS & WILKINS.2026
- **Impact of HER2 expression and <i>ERBB2</i> alterations on clinical outcomes in patients treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.**  
Reyes, K. R., Zhang, L., Cai, E. Y., Thomas, Z., Jiang, C. Y., Oh, E., Jindal, T., Zhong, J., Jaime-Casas, S., Milowsky, M. I., Nizam, A., Shah, S., Basu, et al  
LIPPINCOTT WILLIAMS & WILKINS.2026: 794
- **Outcomes with subsequent therapies post-enfortumab vedotin/pembrolizumab (EVP) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.**  
Jiang, C. Y., Hwang, H., Thomas, Z., Jindal, T., Cai, E. Y., Jang, A., Oh, E., Bakaloudi, D., Tripathi, A., Shah, S., Gupta, S., Grivas, P., Tsung, et al  
LIPPINCOTT WILLIAMS & WILKINS.2026: 705
- **Distance-stratified sociodemographic differences in telemedicine use in surgical oncology clinics at an academic medical center.** *NPJ digital medicine*  
Parameswaran, V., Tsung, S., Zeng, Y. B., Miller, M., Pritchett, J., Demaerschalk, B. M., Rosengaus, L., Sharp, C., Lee, B., Shah, S.  
2026
- **Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.** *Clinical genitourinary cancer*  
Jang, A., Jindal, T., Khaki, A. R., Jiang, C. Y., Alhalabi, O., Nguyen, C. B., Tsung, I., Oh, E., Epstein, I., Bakaloudi, D. R., Jaime-Casas, S., Nizam, A., Glover, et al  
2026: 102501
- **Cannonball metastases as an initial presentation of urothelial bladder carcinoma: a case report and literature review.** *Urology case reports*  
Rayapureddi, K., Glover, M., Guo, H. H., Chan, E., Shah, S. A.  
2026; 64: 103320
- **Genomic Landscape and Outcomes of Renal Cell Carcinoma With Metastases to the Pancreas.** *JCO precision oncology*  
Glover, M. J., Ashok, A., Khan, O., Kao, C. S., Chiang, R., Hoerner, C. R., Shah, S. A., Srinivas, S., Fan, A. C., Khaki, A. R.

2025; 9: e2500318

- **Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.** *Urologic oncology*  
Jindal, T., Jiang, C. Y., Alhalabi, O., Davidsohn, M., Freeman, D., Epstein, I. Y., Bakaloudi, D. R., Talukder, R., Nizam, A., Nguyen, C. B., Oh, E., Tsung, I., Glover, et al  
2025
- **Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.** *The oncologist*  
Jiang, C. Y., Hwang, H., Epstein, I. Y., Bakaloudi, D. R., Talukder, R., Taylor, A. K., Nizam, A., Jindal, T., Glover, M. J., Khaki, A. R., Barata, P. C., Nguyen, C. B., Oh, et al  
2025
- **Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.** *Cancer medicine*  
Nizam, A., Nguyen, C. B., Li, J., Zabor, E. C., Msaouel, P., Jiang, C. Y., Alhalabi, O., Oh, E., Davidsohn, M. P., Epstein, I. B., Bakaloudi, D. R., Talukder, R., Jindal, et al  
2025; 14 (19): e71284
- **Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.** *European urology*  
Jindal, T., Jiang, C. Y., Alhalabi, O., Nguyen, C. B., Oh, E., Tsung, I., Bakaloudi, D. R., Talukder, R., Davidsohn, M., Freeman, D., Epstein, I. Y., Ding, C. C., Nizam, et al  
2025
- **A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH).** *The oncologist*  
Chen, W., Majovski, J., Bhatia, S., Chan, A., Grivas, P., Lee, S., Shah, S., Thompson, J. A., Tykodi, S. S., Veatch, J. R., Schapira, L., Hall, E. T.  
2025; 30 (7)
- **ASO Visual Abstract: Telemedicine Trends in Ambulatory Surgical Oncology-A Five-Year Analysis of Visit Volume and Utilization at a High-Volume Academic Center.** *Annals of surgical oncology*  
Parameswaran, V., Miller, M., Pritchett, J., Demaerschalk, B., Hu, Y., Tsung, S., Zeng, Y. B., Rosengaus, L., Sharp, C., Lee, B., Shah, S.  
2025
- **Telemedicine Trends in Ambulatory Surgical Oncology: A Five-Year Analysis of Visit Volume and Utilization at a High-Volume Academic Center.** *Annals of surgical oncology*  
Parameswaran, V., Miller, M., Pritchett, J., Demaerschalk, B., Hu, Y., Tsung, S., Zeng, Y. B., Rosengaus, L., Sharp, C., Lee, B., Shah, S.  
2025
- **Comparing trends in telehealth utilization by medical oncology practices at Stanford Medicine and Mayo Clinic from 2019-2023.**  
Parameswaran, V., Miller, M., Grimm, J., Gullerud, R., Fan, W., Gibbons, D., Oyarzabal, B., Lunde, J., Coffey, J., Harper, S., Rosengaus, L., Sharp, C., Shah, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: e13890
- **Impact of telemedicine on access to care in surgical oncology clinics: Distance and time to visit analysis for new patients at a multispecialty cancer center.**  
Parameswaran, V., Tsung, S., Zeng, Y., Miller, M., Pritchett, J. C., Demaerschalk, B., Rosengaus, L., Sharp, C., Lee, B., Shah, S.  
LIPPINCOTT WILLIAMS & WILKINS.2025: e23345
- **Association of tumor-informed ctDNA-based molecular residual disease (MRD) with clinical outcomes for upper tract urothelial cancer (UTUC).**  
Ayanambakkam, A., Laliotis, G., Reyes, K. R., Mitchell, B., Au, C., Glover, M., Meagher, M. F., Dutta, P., Sharma, S., Malhotra, M., Elnaggar, A., Liu, M. C., Patel, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: 4565
- **NCCN Guidelines Insights: Testicular Cancer, Version 2.2025.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Gilligan, T., Lin, D. W., Adra, N., Bagrodia, A., Feldman, D. R., Yamoah, K., Aggarwal, R., Chandrasekar, T., Costa, D., Drakaki, A., Eggener, S., Enamekhoo, H., Geynisman, et al  
2025; 23 (4)

- **Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report.** *Case reports in oncology*  
Glover, M., Beshar, I., McHenry, A., Ding, C., Dorigo, O., Chan, E., Shah, S. A.  
2025; 18 (1): 473-479
- **Virtual Second-Opinion Delivery for Oncology Patients.** *JCO oncology practice*  
Shah, A. P., Shi, S., Sun, T. Y., Patel, M. I., Shah, S. A.  
2025: OP2400392
- **Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study.**  
Jindal, T., Jiang, C. Y., Alhalabi, O., Sidhom, F., Jang, A., Bakaloudi, D., Narula, I., Jaime-Casas, S., Glover, M., Nizam, A., Gupta, S., Bilen, M., Shah, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Outcomes with tandem or triplet autologous stem cell transplant for refractory germ cell tumors.**  
Glover, M., Shah, S., Fan, A. C., Srinivas, S., Khaki, A., Johnston, L. J.  
LIPPINCOTT WILLIAMS & WILKINS.2025
- **PSA response and survival based on metastatic site in patients with metastatic castration resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).**  
Allen, J., Bergstrom, C. P., Song, H., Hoffmann, C., Ruiz, S., Chien, J., Moore, K., Parikh, D., Shah, S., Fan, A. C., Srinivas, S., Iagaru, A., Khaki, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.** *European urology oncology*  
Jindal, T., Jiang, C., Alhalabi, O., Nizam, A., Nguyen, C., Talukder, R., Bakaloudi, D., Davidsohn, M., Freeman, D., Glover, M., Khaki, A. R., Evans, S., Lemke, et al  
2024
- **Real-world implementation of an EHR-integrated, SMS text remote patient monitoring platform at an academic cancer center**  
Shah, S., Kadurugamuwa, G., Tisch, A., Lu, M., Modarresi, S., Johnston, C., Colbert, J.  
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study.**  
Jiang, C. Y., Jindal, T., Epstein, I. B., Nguyen, C. B., Nizam, A., Bakaloudi, D., Taylor, A. K., Milowsky, M. I., Shah, S., Hoimes, C. J., Bilen, M., Zakharia, Y., Emamekhoo, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Coaches Activating, Reaching, and Engaging Patients to Engage in Advance Care Planning: A Randomized Clinical Trial.** *JAMA oncology*  
Rodriguez, G. M., Parikh, D. A., Kappahn, K., Gupta, D. M., Fan, A. C., Shah, S., Srinivas, S., Teuteberg, W., Seevaratnam, B., Asuncion, K., Chien, J., Moore, K., Ruiz, et al  
2024
- **Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.** *European journal of nuclear medicine and molecular imaging*  
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Shah, J., Bergstrom, C. P., Fan, A. C., Shah, S., Khaki, et al  
2024
- **Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program.** *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*  
Parikh, D. A., Rodriguez, G. M., Ragavan, M., Kerr, E., Asuncion, M. K., Hansen, J., Srinivas, S., Fan, A. C., Shah, S., Patel, M. I.  
2024; 32 (3): 161
- **Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC).**  
Bolan, P., Hui, G., Low, Y., Gombar, S., Fan, A. C., Parikh, D., Shah, S., Srinivas, S., Khaki, A.  
LIPPINCOTT WILLIAMS & WILKINS.2024: 402

- **Outcomes with neoadjuvant chemotherapy in bladder-preserving treatment for MIBC**  
Glover, M., Ewongwo, A., Usoz, M., Kornberg, Z., Bagshaw, H., Shah, J., Shah, S., Qian, Y.  
LIPPINCOTT WILLIAMS & WILKINS.2024: 577
- **Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.**  
Jindal, T., Alhalabi, O., Nguyen, C. B., Bakaloudi, D., Nizam, A., Bilen, M., Basu, A., Zakharia, Y., Milowsky, M. I., Brown, J. R., Kilari, D., Shah, S., Emamekhoo, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024: 651
- **Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database**  
Jiang, C. Y., Hwang, H., Jindal, T., Qiao, W., Epstein, I., Nguyen, C. B., Gupta, S., Shah, S., Bilen, M., Milowsky, M. I., Hoimes, C. J., Kilari, D., Zakharia, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of <SUP>177</SUP>Lu-PSMA-617 treatment.**  
Leonio, M., Ferri, V., Duan, H., Shah, J., Moradi, F., Mari Aparici, C., Franc, B., Davidzon, G., Bergstrom, C. P., Fan, A. C., Shah, S., Khaki, A., Srinivas, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024: 32
- **Total and anatomically contextualized quantitative <SUP>18</SUP>F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer.**  
Song, H., Anand, A., Sjostrand, K., Ferri, V., Duan, H., Shah, J., Moradi, F., Aparici, C., Franc, B., Davidzon, G., Bergstrom, C. P., Fan, A. C., Shah, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024: 33
- **Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT)**  
Bergstrom, C. P., Song, H., Ruiz, S., Chien, J., Moore, K., Parikh, D., Shah, S., Fan, A. C., Srinivas, S., Iagaru, A., Khaki, A.  
LIPPINCOTT WILLIAMS & WILKINS.2024: 86
- **COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. *Translational oncology***  
Moey, M. Y., Hennessy, C., French, B., Warner, J. L., Tucker, M. D., Hausrath, D. J., Shah, D. P., DeCara, J. M., Bakouny, Z., Labaki, C., Choueiri, T. K., Dent, S., Akhter, et al  
2023; 34: 101709
- **Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes**  
Glover, M., Chiang, R. S., Hoerner, C. R., Khan, O. A., Kao, C., Shah, S., Srinivas, S., Fan, A. C., Khaki, A.  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.**  
Jindal, T., Zhang, L., Jiang, C., Kilari, D., Alhalabi, O., Nizam, A., Basu, A., Bilen, M., Zakharia, Y., Milowsky, M. I., Shah, S., Hoimes, C. J., Davis, et al  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis**  
Kommalapati, A., Laliotis, G., Glover, M., Selig, G., Kollipara, R., Mahmood, T., Shah, S., Hoimes, C. J., Stewart, T. F., Sharma, S., Malhotra, M., Pajak, N., Calhoun, et al  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma. *BMC cancer***  
Johnson, D. B., Atkins, M. B., Hennessy, C., Wise-Draper, T., Heilman, H., Awosika, J., Bakouny, Z., Labaki, C., Saliby, R. M., Hwang, C., Singh, S. R., Balanchivadze, N., Friese, et al  
2023; 23 (1): 265
- **Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.**  
Khaki, A., Fan, A. C., Shah, S., Parikh, D., Chien, J., Moore, K., Ruiz, S., Haas, D., Fakhoury, L., Del Toro, N., Baker, P., O'Brien, A., Srinivas, et al

LIPPINCOTT WILLIAMS & WILKINS.2023

- **Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.**  
Jindal, T., Kilari, D., Alhalabi, O., Nizam, A., Khaki, A., Basu, A., Barata, P. C., Bilen, M., Shah, S., Zakharia, Y., Milowsky, M. I., Bellmunt, J., Emamekhoo, et al  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).**  
Koshkin, V. S., Henderson, N., Kilari, D., Jindal, T., Alhalabi, O., Freeman, D., Basu, A., Barata, P. C., Bilen, M., Zakharia, Y., Emamekhoo, H., Shah, S., Milowsky, et al  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.** *European urology*  
Molina, G. E., Schwartz, B., Srinivas, S., Shah, S., Zaba, L. C.  
2023
- **Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population.** *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*  
Lichtensztajn, D. Y., Hofer, B. M., Leppert, J. T., Brooks, J. D., Chung, B. I., Shah, S. A., DeRouen, M. C., Cheng, I.  
2022
- **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*  
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al  
2022: OP2200128
- **Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.** *JAMA oncology*  
Bakouny, Z., Labaki, C., Grover, P., Awosika, J., Gulati, S., Hsu, C. Y., Alimohamed, S. I., Bashir, B., Berg, S., Bilen, M. A., Bowles, D., Castellano, C., Desai, et al  
2022
- **Characterization of remote second-opinion oncology patients and associated changes in management.**  
Shah, A. P., Shi, S., Shah, S.  
LIPPINCOTT WILLIAMS & WILKINS.2022: E18563
- **Post-acute sequelae of SARS-CoV-2 infection in patients with cancer.**  
Warner, J., Pinato, D., Mishra, S., Saliby, R., Hwang, C., Gulati, S., Mckay, R. R., Labaki, C., Griffiths, E. A., Jani, C., Yu, P., Portuguese, A., Puc, et al  
LIPPINCOTT WILLIAMS & WILKINS.2022: E18746
- **COVID-19 in patients with gynecologic cancer: A preliminary report from the COVID-19 and Cancer Consortium (CCC19).**  
Beeghly-Fadiel, A., Prescott, L. S., Ruiz-Garcia, E., Hwang, C., Heilman, H., Mckay, R. R., Saliby, R., Lau, S., Nagaraj, G., Puc, M., Zsiros, E., Shah, S., Jani, et al  
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysis.** *Blood cancer discovery*  
Rubinstein, S. M., Bhutani, D., Lynch, R. C., Hsu, C., Shyr, Y., Advani, S., Mesa, R. A., Mishra, S., Mundt, D. P., Shah, D. P., Sica, R. A., Stockerl-Goldstein, K. E., Stratton, et al  
2022
- **Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.** *Open forum infectious diseases*  
Satyanarayana, G., Enriquez, K. T., Sun, T., Klein, E. J., Abidi, M., Advani, S. M., Awosika, J., Bakouny, Z., Bashir, B., Berg, S., Bernardes, M., Egan, P. C., Elkrief, et al  
2022; 9 (3): ofac037
- **Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population.**

Chiang, R. S., Ashok, A., Mauer, E., Barrett, A., Hoerner, C. R., Khan, O. A., Kao, C., Shah, S., Srinivas, S., Fan, A. C., Khaki, A.  
LIPPINCOTT WILLIAMS & WILKINS.2022

- **Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.** *JAMA network open*  
Hawley, J. E., Sun, T., Chism, D. D., Duma, N., Fu, J. C., Gatson, N. T., Mishra, S., Nguyen, R. H., Reid, S. A., Serrano, O. K., Singh, S. R., Venepalli, N. K., Bakouny, et al  
1800; 5 (1): e2142046
- **Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.** *Cancer*  
Koshkin, V. S., Henderson, N., James, M., Natesan, D., Freeman, D., Nizam, A., Su, C. T., Khaki, A. R., Osterman, C. K., Glover, M. J., Chiang, R., Makrakis, D., Talukder, et al  
2021
- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**  
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.** *Journal of patient-reported outcomes*  
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., Velazquez, B., Chu, G., Bruzzone, B., Cabot, A., Fisher, G. A., Srinivas, S., Fan, et al  
2021; 5 (1): 91
- **Patterns in cancer management changes for patients with COVID-19 in northern California.**  
Glover, M., Wu, J., Kwon, D. H., Zhang, S., Henry, S., Wood, D., Rubin, D., Borno, H., Small, E., Schapira, L., Koshkin, V. S., Shah, S.  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Reply to R. Kebudi et al.** *JCO oncology practice*  
Tsu-Yu Wu, J., Kwon, D. H., Glover, M., Henry, S., Wood, D., Rubin, D., Koshkin, V., Schapira, L., Shah, S. A.  
2021: OP2100105
- **PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., Hancock, S., Shah, S. A., Srinivas, S., Swift, P., Moradi, F., Davidzon, G. A., Iagaru, et al  
2021
- **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*  
Waliyany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.  
2021; 3 (1): 137-39
- **Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study.** *Urologic oncology*  
Bhambhvani, H. P., Greenberg, D. R., Kasman, A. M., DeRouen, M. C., Cheng, I., Eisenberg, M. L., Shah, S. A.  
2021
- **Remote Oncology Care: Review of Current Technology and Future Directions.** *Cureus*  
McGregor, B. A., Vidal, G. A., Shah, S. A., Mitchell, J. D., Hendifar, A. E.  
2020; 12 (8): e10156
- **Remote Oncology Care: Review of Current Technology and Future Directions** *CUREUS*  
McGregor, B. A., Vidal, G. A., Shah, S. A., Mitchell, J. D., Hendifar, A. E.  
2020; 12 (8)
- **Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study.** *Cancer discovery*  
Rivera, D. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C., Rubinstein, S. M., Lee, B. J., Choueiri, T. K., de Lima Lopes, G., Grivas, P., Painter, C. A., Rini, et al

2020

- **Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.** *Urologic oncology*  
Bhambhani, H. P., Zamora, A., Shkolyar, E., Prado, K., Greenberg, D. R., Kasman, A. M., Liao, J., Shah, S., Srinivas, S., Skinner, E. C., Shah, J. B.  
2020
- **Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19)**  
Rubinstein, S., Grivas, P., Choueiri, T. K., Kuderer, N., Shah, D., Rivera, D. R., Gupta, S., Bilen, M., Halfdanarson, T., Doroshow, D., Wehbe, F., Shah, S., Shyr, et al  
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Association of renal cell carcinoma subtypes with race/ethnicity and comorbid medical conditions**  
Lichtensztajn, D. Y., Hofer, B. M., Leppert, J. T., Brooks, J. D., Chung, B., Shah, S. A., DeRouen, M. C., Gomez, S. L., Cheng, I.  
AMER ASSOC CANCER RESEARCH.2020
- **Testicular cancer in Hispanics: Incidence of subtypes over time according to neighborhood sociodemographic factors in California**  
DeRouen, M. C., McKinley, M., Shah, S. A., Borno, H. T., Aoki, R., Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Chung, B., Gomez, S. L., Cheng, I.  
AMER ASSOC CANCER RESEARCH.2020
- **Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California.** *Cancer causes & control : CCC*  
DeRouen, M. C., McKinley, M., Shah, S. A., Borno, H. T., Aoki, R., Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Chung, B. I., Gomez, S. L., Cheng, I.  
2020
- **DEVELOPING THE ADVANCED PRACTICE ROLE IN INFUSION TREATMENT AREA**  
Shah, D., Kuriakose, C., Healy, D., Shah, S.  
ONCOLOGY NURSING SOC.2020
- **Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.** *Journal for immunotherapy of cancer*  
Martinez Chanza, N., Xie, W., Issa, M., Dzimitrowicz, H., Tripathi, A., Beuselinck, B., Lam, E., Zakharia, Y., Mckay, R., Shah, S., Mortazavi, A., R Harrison, M., Sideris, et al  
2020; 8 (1)
- **Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California.** *JCO oncology practice*  
Wu, J. T., Kwon, D. H., Glover, M. J., Henry, S. n., Wood, D. n., Rubin, D. L., Koshkin, V. S., Schapira, L. n., Shah, S. A.  
2020: OP2000790
- **Feasibility and design of a cloud-based digital platform in patients with advanced cancer.**  
Roy, M., Hall, E., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., San Pedro-Salcedo, M., Wakelee, H. A., Neal, J. W., Padda, S., Das, M., Fan, A. C., Srinivas, et al  
AMER SOC CLINICAL ONCOLOGY.2019
- **Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).**  
Chanza, N., Xie, W., Issa, M., Dzimitrowicz, H., Tripathi, A., Beuselinck, B., Lam, E., Zakharia, Y., Mckay, R. R., Shah, S., Mortazavi, A., Harrison, M., Choueiri, et al  
AMER SOC CLINICAL ONCOLOGY.2019
- **Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study** *LANCET ONCOLOGY*  
Changa, N., Xie, W., Bilen, M., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., Balakrishnan, A., Bowman, I., Jain, R., Stadler, W., Zakharia, Y., Narayan, V., Beuselinck, et al  
2019; 20 (4): 581–90
- **Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Shah, S. A., Sieh, W., Chung, B. I., Gomez, S. L., Cheng, I.  
2018; 16 (11): 1353–60

- **Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Shah, S. A., Sieh, W., Chung, B., Gomez, S. L., Cheng, I.  
2018; 16 (11): 1353-1360
- **A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.**  
Sikic, B. I., Lakhani, N. J., Patnaik, A., Shah, S., Chandana, S. R., Rasco, D. W., Colevas, A., O'Rourke, T. J., Papadopoulos, K. P., Fisher, G. A., Chao, M., Agoram, B., Chen, et al  
AMER SOC CLINICAL ONCOLOGY.2018
- **Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.**  
Chanza, N., Bosse, D., Bilen, M., Geynisman, D. M., Balakrishnan, A., Jain, R. K., Bowman, I., Zakharia, Y., Narayan, V., Beuselinck, B., Agarwal, N., McKay, R. R., Hsu, et al  
AMER SOC CLINICAL ONCOLOGY.2018
- **The CD47 Macrophage Checkpoint as a New Immunotherapy Target**  
Sikic, B. I., Padda, S. K., Shah, S. A., Colevas, D., Narayanan, S., Fisher, G. A., Supan, D., Wakelee, H. A., Aoki, R., Pegram, M. D., Villalobos, V. M., Liu, J., Takimoto, et al  
ELSEVIER SCIENCE INC.2017: S108–S109
- **A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers**  
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al  
AMER SOC CLINICAL ONCOLOGY.2016
- **Prognostic factors for pancreatic metastases in renal cell cancer.**  
Chung, A., Li, S., Shah, S., Fan, A. C., Srinivas, S.  
AMER SOC CLINICAL ONCOLOGY.2016
- **In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study** *BLOOD*  
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., Morales, A., Abdulla, F., Xing, L., Navi, D., Tibshirani, R. J., Advani, R. H., Lingala, et al  
2012; 119 (2): 355-363
- **Preliminary report on a phase I/II study of intratumoral injection of PF-3512676 (CpG 7909), a TLR9 agonist, combined with radiation in recurrent low-grade lymphomas.** *48th Annual Meeting of the American-Society-of-Hematology*  
Ai, W. Y., Kim, Y., Hoppe, R. T., Shah, S., Horning, S. J., Tibshirani, R., Levy, R.  
AMER SOC HEMATOLOGY.2006: 767A–768A